The Latest Advancement in Regenerative Medicine Is Lab-Grown Vaginas

Medical research continues to succeed in engineering organs. But that’s not enough.

Yes, that is what the headline implies.
National Journal
Brian Resnick
Add to Briefcase
Brian Resnick
April 10, 2014, 2:30 p.m.

Add nos­trils and va­gi­nas to the read­ily ex­pand­ing list of hu­man tis­sues doc­tors can now grow in labor­at­or­ies and suc­cess­fully im­plant in pa­tients.

Two long-term stud­ies just pub­lished in the in­flu­en­tial med­ic­al journ­al The Lan­cet out­line the suc­cess doc­tors have achieved in trans­plant­ing both body parts. In the first study, doc­tors at Wake Forest Uni­versity har­ves­ted cells from the gen­it­als of four teen­age girls born with a syn­drome that res­ults in un­der­developed sexu­al or­gans, coaxed those cells in­to a re­gen­er­at­ive state, grew them on a scaf­fold, and then trans­planted the res­ult­ing tis­sue.

After eight years of fol­low up, “the or­gans con­tin­ue to func­tion as if they were nat­ive tis­sue and all re­cip­i­ents are sexu­ally act­ive, re­port no pain, and are sat­is­fied with their de­sire/arous­al, lub­ric­a­tion, and or­gasm.”

In the second study, five people had their nos­trils re­con­struc­ted with their own car­til­age. That tis­sue was har­ves­ted from their own noses, and coaxed in­to ex­pand­ing in volume by a factor of 40. It was then im­planted. The re­search con­cludes that “the clin­ic­al re­con­struc­tion of the nas­al [lobe] after re­sec­tion of a non-melan­oma skin can­cer is safe and feas­ible.”

While these find­ings are cer­tainly eye­brow-rais­ing — and lend hope to those suf­fer­ing with dis­fig­ur­a­tion — the more im­port­ant as­pect of their pub­lic­a­tion can be found in an op-ed pub­lished along­side the re­search.

Drs. Mar­tin A. Birch­all, and Al­ex­an­der M. Sei­fali­an write that these find­ings can be just as frus­trat­ing as they are prom­ising. This re­search is con­sidered dis­rupt­ive medi­cine, and dis­rup­tions can take a very, very long time to make their way in­to main­stream medi­cine. And the high cost of de­vel­op­ing such tech­no­logy of­ten poses road­b­locks. Birch­all and Sei­fali­an write:

MRI scan­ners con­tin­ue to im­prove gen­er­a­tion­ally. These changes, which im­prove the pa­tient’s ex­per­i­ence and ac­cur­acy of dia­gnos­is, are sus­tain­ing in­nov­a­tions: they im­prove an ex­ist­ing sys­tem that is un­der­stood by pa­tients and that sup­ports spe­cial­ised in­dustry, doc­tors, and health-care sys­tems. By con­trast, tis­sue en­gin­eer­ing, and the vari­ous shades of re­gen­er­at­ive and cel­lu­lar ther­apies it part­ners, is a dis­rupt­ive tech­no­logy. …

Early auto­mobile tech­no­logy, al­though highly in­nov­at­ive, was the pre­serve of those who could af­ford it for many years. It was only when Henry Ford’s mass pro­duc­tion brought auto­mo­biles to every­one’s street, in num­bers yet at af­ford­able cost, that the in­dustry of the horse-drawn car­riage passed away. These two Lan­cet stud­ies show that those who prac­tise con­ven­tion­al tis­sue re­con­struc­tion and or­gan trans­plant­a­tion, and the health-care and com­mer­cial in­dus­tries which sup­port them, should fi­nally be tak­ing the quirky min­nows of tis­sue en­gin­eer­ing quite ser­i­ously. Dis­rupt­ive in­nov­a­tion might be nigh.

As I wrote in Novem­ber, it will be some time be­fore lab-grown or­gans are com­monly avail­able. Clin­ic­al tri­als for new pro­ced­ures take dec­ades. And “private in­dustry is go­ing to have to raise mil­lions and mil­lions of dol­lars not around the sci­ence, but around the prac­tic­al­ity,” Wil­li­am Wag­n­er, dir­ect­or of re­gen­er­at­ive medi­cine at the Uni­versity of Pitt­s­burgh, told me then.

Road­b­locks in­volving time and money are not ex­clus­ive to re­gen­er­at­ive medi­cine. Take an­ti­bi­ot­ic re­search. Ap­provals of new an­ti­bi­ot­ics are cur­rently at their low­est rate, at a time when threat of drug-res­ist­ant strains haven’t been high­er. Or even sun­screen. In­gredi­ents that European com­pan­ies have been us­ing for years, which work bet­ter than the ones cur­rently avail­able in the United States, are stuck in reg­u­lat­ory limbo.

That’s why Birch­all and Sei­fali­an provide a good re­mind­er: Let’s turn some of these gee-whiz stud­ies in­to real­ity.

What We're Following See More »
Chef Jose Andres Campaigns With Clinton
0 minute ago
White House Weighs in Against Non-Compete Contracts
46 minutes ago

"The Obama administration on Tuesday called on U.S. states to ban agreements prohibiting many workers from moving to their employers’ rivals, saying it would lead to a more competitive labor market and faster wage growth. The administration said so-called non-compete agreements interfere with worker mobility and states should consider barring companies from requiring low-wage workers and other employees who are not privy to trade secrets or other special circumstances to sign them."

House Investigators Already Sharpening Their Spears for Clinton
1 hours ago

House Oversight Committee Chairman Jason Chaffetz plans to spend "years, come January, probing the record of a President Hillary Clinton." Chaffetz told the Washington Post: “It’s a target-rich environment. Even before we get to Day One, we’ve got two years’ worth of material already lined up. She has four years of history at the State Department, and it ain’t good.”

No Lobbying Clinton’s Transition Team
4 hours ago

Hillary Clinton's transition team has in place strict rules to limit the influence that lobbyists could have "in crafting the nominee’s policy agenda." The move makes it unlikely, at least for now, that Clinton would overturn Obama's executive order limiting the role that lobbyists play in government

Federal Government Employees Giving Money to Clinton
4 hours ago

Federal employees from 14 agencies have given nearly $2 million in campaign donations in the presidential race thus far, and 95 percent of the donations, totaling $1.9 million, have been to the Clinton campaign. Employees at the State Department, which Clinton lead for four years, has given 99 percent of its donations to the Democratic nominee.


Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.